Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

Minocycline

minocycline
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Ximino CAPSULE, EXTENDED RELEASE, ORAL 45 mg, 90 mg, 135 mg    
Dynacin, Minocin, Vectrin CAPSULE, ORAL 50 mg, 100 mg      
Minocin CAPSULE, ORAL 75 mg    
Zilxi FOAM, TOPICAL 1.5%      
Minocin POWDER FOR INJECTION, INTRAVENOUS 100 mg      
Solodyn TABLET, EXTENDED RELEASE, ORAL 45 mg, 55 mg, 65 mg, 80 mg    
Solodyn TABLET, EXTENDED RELEASE, ORAL 90 mg, 105 mg, 115 mg, 135 mg    

VIEW MORE Tetracyclines
CLASS
081224

Comments:
ORDERED FORMULATION THERAPEUTIC INTERCHANGE NOTES
minocycline ER  (Solodyn)
  • 45 mg ER oral tablet Daily
  • 55 mg ER oral tablet Daily
  • 65 mg ER oral tablet Daily
  • 80 mg ER oral tablet Daily
  • 90 mg ER oral tablet Daily
  • 105 mg ER oral tablet Daily
  • 115 mg ER oral tablet Daily
  • 135 mg ER oral tablet Daily
minocycline (Minocin)
  • 50 mg oral capsule Daily
  • 50 mg oral capsule Daily
  • 50 mg oral capsule Daily
  • 50 mg oral capsule BID
  • 50 mg oral capsule BID
  • 50 mg oral capsule BID
  • 50 mg oral capsule BID
  • 100 mg oral capsule BID
 
 
minocycline (Minocin)
  • 75 mg oral capsule BID
minocycline (Minocin)
  • 100 mg oral capsule BID
 

minocycline (Ximino)

  • 45 mg once daily
  • 90 mg once daily
  • 135 mg once daily

minocycline (Minocin)

  • 50 mg oral capsule Daily
  • 50 mg oral capsule BID
  • 100 mg oral capsule BID
 

Oral acne and periodontal indications are non-formulary. If medication needed for non-formulary use, recommend that patient to use own supply.

Minocycline injection is classified as formulary, restricted to Infectious Disease.


Ximino is non formulary with an interchange to generic minocycline.


Zilxi - Inpatients may use home supply. Alternative formulation products are available for inpatient use.


Reviewed: October 26, 2010 (SOLODYN),  April 26, 2011 (SOLODYN), 25 March 2015 (Minocin IV), and 23 August 2016 (Minocycline 75 mg), 22 May 2018 (Ximino), Jan 2023 (Zilxi)

 

Spotlight Minocycline Topical Foam (Zilxi)


Last updated: Jul. 16, 2024







This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.